Idiopathic pulmonary fibrosis (IPF), the most common form of idiopathic interstitial
pneumonia, is a progressive, irreversible, and typically lethal disease characterized by an …

Idiopathic pulmonary fibrosis is a prototype of chronic, progressive, and fibrotic lung disease.
Healthy tissue is replaced by altered extracellular matrix and alveolar architecture is …

Background: This document provides clinical recommendations for the diagnosis of
idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American …

Little is known about the relative importance of monocyte and tissue-resident macrophages
in the development of lung fibrosis. We show that specific genetic deletion of monocyte …

Acute exacerbation of idiopathic pulmonary fibrosis has been defined as an acute, clinically
significant, respiratory deterioration of unidentifiable cause. The objective of this …

Rheumatoid arthritis is an autoimmune disease that primarily affects the joints. The
emergence of highly effective anti-rheumatic drugs such as biologic agents and janus …

Background Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that
targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of …

Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterised by chronic,
progressive scarring of the lungs and the pathological hallmark of usual interstitial …

Background: In 2002 the American Thoracic Society/European Respiratory Society
(ATS/ERS) classification of idiopathic interstitial pneumonias (IIPs) defined seven specific …

Abstract Background and purpose The Phase II TOMORROW trial and two Phase III
INPULSIS® trials investigated the efficacy and safety of nintedanib versus placebo in …